glutathione dependent transporter transporters. Plasma membrane GSH efflux pumps . Two GSH Dual localization of glutathione S‐transferase

Key concepts in bridging therapies: Biologic modifiers are available to treat specific diseases Outcome of long-term therapy needs to be studied Optimising patient status prior to HSCT with such agents is useful to improve outcome Conditioning Historically, conditioning therapy prior to HSCT for patients with IEI was based on the alkylating agents busulfan and cyclophosphamide

Q10 deficiency: How to fix it There are several reasons why you may not have enough coenzyme Q10: A blockage of the production pathway due to medication: Treatment with statins, i.e

The withdrawal reflected commercial considerations rather than safety concerns

Incorporating analogous mitochondria directed GSH-sensing reporters into nanoplatforms would allow simultaneous readout and modulation of intramitochondrial redox status, enabling closed-loop theranostic schemes i.e